Clinical trial · Observational
Prognostic Factors for Survival in Patients With Cholangiocarcinoma
NCT06369480CI-TRIAL-00076196unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The objective of this retrospective study is to determine the survival rates of CCA patients based on different therapeutic approaches. Additionally, we aim to investigate the risk factors associated with poor survival within a cohort of patients treated over a seven-year period across four Danish hospitals. We anticipate that our findings could provide additional evidence for clinical decision-making, improve patient outcomes, and contribute to the knowledge in the field.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cholangiocarcinoma | Cholangiocarcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (5)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Best supportive care | Procedure | — | UNRESOLVED |
| Neoadjuvant chemotherapy | Procedure | — | UNRESOLVED |
| Palliative chemotherapy | Procedure | — | UNRESOLVED |
| Resection/Ablation of tumor | Procedure | — | UNRESOLVED |
| Stereotatic radiotherapy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Cholangiocarcinoma
- description
- Patients with diagnosis of Cholangiocarcinoma confirmed by MDT
- interventionNames
- Procedure: Resection/Ablation of tumor
- Procedure: Palliative chemotherapy
- Procedure: Neoadjuvant chemotherapy
- Procedure: Stereotatic radiotherapy
- Procedure: Best supportive care
Primary outcomes (2)
- measure
- Aim I
- timeFrame
- 6 months
- description
- Determine the survival rates of CCA patients based on various therapeutic approaches following the MDT decision.
- measure
- Aim II
- timeFrame
- 6 months
- description
- Determine the risk factors associated with unfavorable overall survival in CCA patients.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Patients' eligibility for this study is contingent on a diagnosis of CCA confirmed by the MDT from Aalborg Universitetshospital, Aarhus Universitetshospital, Odense Universitetshospital, and Rigshospitalet in Denmark from 2013 to 2020. Exclusion Criteria: * We will exclude from the analysis all records with more than one interventions. Additionally, all patients whose cholangiocarcinoma diagnosis was canceled following the MDT meeting will be also excluded, as well those with inconsistent data regarding date of reference to the MDT.
References
Publications (6)
- BACKGROUNDTawarungruang C, Khuntikeo N, Chamadol N, Laopaiboon V, Thuanman J, Thinkhamrop K, Kelly M, Thinkhamrop B. Survival after surgery among patients with cholangiocarcinoma in Northeast Thailand according to anatomical and morphological classification. BMC Cancer. 2021 May 3;21(1):497. doi: 10.1186/s12885-021-08247-z. PMID 33941120
- BACKGROUNDThuehoj AU, Andersen NC, Worm ES, Hoyer M, Tabaksblat EM, Weber B, Mortensen HR. Clinical outcomes after stereotactic ablative radiotherapy in locally advanced cholangiocarcinoma. Acta Oncol. 2022 Feb;61(2):197-201. doi: 10.1080/0284186X.2021.1995893. Epub 2021 Nov 2. No abstract available. PMID 34726565
- BACKGROUNDCillo U, Fondevila C, Donadon M, Gringeri E, Mocchegiani F, Schlitt HJ, Ijzermans JNM, Vivarelli M, Zieniewicz K, Olde Damink SWM, Groot Koerkamp B. Surgery for cholangiocarcinoma. Liver Int. 2019 May;39 Suppl 1(Suppl Suppl 1):143-155. doi: 10.1111/liv.14089. PMID 30843343
- BACKGROUNDMoris D, Palta M, Kim C, Allen PJ, Morse MA, Lidsky ME. Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians. CA Cancer J Clin. 2023 Mar;73(2):198-222. doi: 10.3322/caac.21759. Epub 2022 Oct 19. PMID 36260350
- BACKGROUNDLi Y, Song Y, Liu S. The new insight of treatment in Cholangiocarcinoma. J Cancer. 2022 Jan 1;13(2):450-464. doi: 10.7150/jca.68264. eCollection 2022. PMID 35069894
- BACKGROUNDMa KW, Cheung TT, Leung B, She BWH, Chok KSH, Chan ACY, Dai WC, Lo CM. Adjuvant chemotherapy improves oncological outcomes of resectable intrahepatic cholangiocarcinoma: A meta-analysis. Medicine (Baltimore). 2019 Feb;98(5):e14013. doi: 10.1097/MD.0000000000014013. PMID 30702559